You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Cystadenocarcinoma, Serous

Showing 1 - 25 of 403
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial (Sovilnesib)

Not yet recruiting
  • High Grade Serous Adenocarcinoma of Ovary
  • +3 more
  • (no location specified)
Oct 13, 2023

Malignant Tumors of Female Genital Organs Trial in Houston (Fulvestrant, Abemaciclib)

Active, not recruiting
  • Malignant Neoplasms of Female Genital Organs
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 5, 2022

Endometrial Cancer, Serous Adenocarcinoma, Uterine Tumor Trial (Niraparib oral capsule)

Not yet recruiting
  • Endometrial Cancer
  • +2 more
  • Niraparib oral capsule
  • (no location specified)
Oct 31, 2022

Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer Trial in Toronto (Niraparib)

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • Toronto, Ontario, Canada
    Sunnybrook Research Institute
Jul 18, 2023

Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary Trial in Brescia, Genova (Letrozole tablets, carboplatin

Recruiting
  • Carcinoma, Ovarian Epithelial
  • Low Grade Serous Adenocarcinoma of Ovary
  • Letrozole tablets
  • carboplatin AUC 5 and paclitaxel 175 mg/m2
  • Brescia, BS, Italy
  • +1 more
Oct 26, 2022

Tumor, Ovarian, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer Trial (AVB-001 (Dose Escalation Phase), AVB-001 (Dose

Not yet recruiting
  • Neoplasm, Ovarian
  • +7 more
  • AVB-001 (Dose Escalation Phase)
  • AVB-001 (Dose Expansion Phase)
  • (no location specified)
Sep 15, 2022

Uterine Cancer Trial in Boston (AZD1775)

Recruiting
  • Uterine Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jul 5, 2022

Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Cetntre
Sep 25, 2023

Ovarian Cancer, Relapsed Ovarian Cancer, Fallopian Tube Cancer Trial (Carboplatin)

Not yet recruiting
  • Ovarian Cancer
  • +6 more
  • (no location specified)
Oct 27, 2022

Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma Trial in Atlanta (Atovaquone, Biopsy, Computed

Not yet recruiting
  • Ovarian High Grade Serous Adenocarcinoma
  • Platinum-Resistant Ovarian Carcinoma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Aug 11, 2023

High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Peritoneal High Grade Serous

Recruiting
  • High Grade Fallopian Tube Serous Adenocarcinoma
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Patients With Low Grade Ovarian or Peritoneal Tumors

Recruiting
  • Low Grade Ovarian Serous Adenocarcinoma
  • +5 more
  • Biospecimen Collection
  • Electronic Health Record Review
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Tumor Trial in Rochester

Active, not recruiting
  • Fallopian Tube Clear Cell Adenocarcinoma
  • +22 more
  • Laboratory Biomarker Analysis
  • Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
  • Rochester, Minnesota
    Mayo Clinic
Oct 7, 2022

Recurrent Endometrial Serous Adenocarcinoma Trial in Columbus (procedure, biological, drug)

Not yet recruiting
  • Recurrent Endometrial Serous Adenocarcinoma
  • Biospecimen Collection
  • +4 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 12, 2023

Gynecologic Cancer, Ovarian Cancer, High Grade Serous Carcinoma Trial in Ljubljana (Carboplatin)

Recruiting
  • Gynecologic Cancer
  • +3 more
  • Ljubljana, Slovenia
  • +1 more
Aug 6, 2022

BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer Trial in Providence (Talazoparib Oral Capsule)

Active, not recruiting
  • BRCA1 Mutation
  • +4 more
  • Talazoparib Oral Capsule
  • Providence, Rhode Island
  • +1 more
Nov 30, 2022

Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer Trial (VLS-1488)

Not yet recruiting
  • Advanced Solid Tumor
  • +15 more
  • (no location specified)
Jun 2, 2023

Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma Trial in United States (ZB131)

Recruiting
  • Solid Tumor, Adult
  • +4 more
  • Phoenix, Arizona
  • +8 more
Aug 31, 2022

Multi-layer Data to Improve Diagnosis, Predict Therapy

Recruiting
  • High Grade Ovarian Serous Adenocarcinoma
  • WGS and RNA sequencing
  • +2 more
  • Turku, Finland
    Turku University Hospital
Apr 26, 2022

High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer Trial (Olaparib tablet, Navitoclax)

Recruiting
  • High Grade Serous Carcinoma
  • +2 more
  • Toronto, Ontario, Canada
  • +2 more
Nov 28, 2022

Liquid Biopsies and Tumor Molecular Profiling in Predicting

Recruiting
  • Endometrial Clear Cell Adenocarcinoma
  • +5 more
  • Biospecimen Collection
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 3, 2022

Endometrial Cancer, Papillary Serous Endometrial Carcinoma, Uterine Serous Carcinoma Trial in United States (Niraparib)

Recruiting
  • Endometrial Cancer
  • +4 more
  • New Brunswick, New Jersey
  • +4 more
Mar 17, 2022

Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma Trial (AMT-151)

Not yet recruiting
  • Advanced Solid Tumor
  • +18 more
  • (no location specified)
Aug 10, 2022

Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in Aurora

Active, not recruiting
  • Recurrent Endometrial Serous Adenocarcinoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Aurora, Colorado
    University of Colorado Hospital
May 24, 2022

HER2/Neu+ Uterine Serous Carcinoma Trial in Tucson, New Haven, Boston (Afatinib)

Recruiting
  • HER2/Neu+ Uterine Serous Carcinoma
  • Tucson, Arizona
  • +2 more
Feb 2, 2022